Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Herein, we aimed to follow up on the cellular and humoral immune responses of a group of individuals who initially received the CoronaVac vaccine, followed by a booster with the Pfizer vaccine.
Methods: Blood samples were collected: before and 30 days after the first CoronaVac dose; 30, 90, and 180 days after the second CoronaVac dose, and also 20 days after the booster with the Pfizer vaccine.
Results: Whilst the positivity to gamma interferon-type cellular response increased after the first CoronaVac dose, neutralizing and IgG antibody levels only raised 30 days after the second dose, followed by a drop in these responses after 90 and 180 days. The booster with the Pfizer vaccine elicited a robust cellular and humoral response. A higher number of double-negative and senescent T cells, as well as increased pro-inflammatory cytokines levels were found in the participants with lower humoral immune responses.
Conclusion: CoronaVac elicited an early cellular response, followed by a humoral response, which dropped 90 days after the second dose. The booster with the Pfizer vaccine significantly enhanced these responses. Furthermore, a pro-inflammatory systemic status was found in volunteers who presented senescent T cells, which could putatively impair the immune response to vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143893 | PMC |
| http://dx.doi.org/10.3390/vaccines11040840 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recommendations for pneumococcal vaccination of at-risk children: a global overview (2022-2024).
Vaccine
September 2025
Pfizer Vaccines and Antivirals, Medical and Scientific Affairs, Emerging Markets Region, France.
Background: Pneumococcal diseases have a major impact on childhood morbidity and mortality across the world. While any child could be infected, those with certain health conditions have an increased risk of infection and subsequent disease severity. This report provides an overview of pneumococcal vaccination policies focused on children considered to be at particular risk of pneumococcal disease.
View Article and Find Full Text PDFAssessing the impact of childhood pneumococcal vaccination on pneumonia mortality in Colombia: a 14-year analysis.
BMC Public Health
September 2025
Universidad Nacional de Colombia, Bogotá, Colombia.
Background: The 10-valent pneumococcal conjugate vaccine (PCV10) has been offered to all infants through Colombia’s National Immunization Program (NIP) since 2012, with catch-up vaccination until age 5. However, pneumococcal vaccination is not currently included in the NIP for other age groups, such as those ≥ 5 years with medical conditions or older adults. This study assessed the pediatric PCV10 effect on pneumonia mortality rate (MR) trends across different age groups from 2006 to 2019.
View Article and Find Full Text PDFBivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial.
JAMA
August 2025
Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.
Importance: Respiratory syncytial virus (RSV) infection is linked to elevated cardiovascular risk, particularly in individuals with preexisting cardiovascular disease (CVD). A bivalent RSV prefusion F protein (RSVpreF) vaccine was recently approved for preventing RSV-related lower respiratory tract illness, but its effectiveness against cardiovascular outcomes has not been evaluated in a randomized trial.
Objective: To investigate the vaccine effectiveness of RSVpreF compared with no vaccine against cardiovascular outcomes among adults aged 60 years or older.
Third exposure to COVID-19 infection or vaccination differentially impacts T cell responses.
J Infect
August 2025
The Francis Crick Institute, NW1 1AT London, UK; National Institute for Health Research (NIHR) University CollegeLondon Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, UK; Research Department of Infection, Division of Infection and Immunity, University College
Background: In 2021, the rapid rollout of two doses of SARS-CoV-2 vaccines reduced COVID-19 severity and mortality. However, further vaccine doses as a prime-boost schedule were limited, and lifting of public health restrictions by late 2021 frequently led to infection, rather than vaccine, as a third exposure.
Objective: To compare how the third exposure through mRNA booster or SARS-CoV-2 infection shapes humoral and cellular immunity following two vaccine doses.
Humoral and Cellular Immune Responses Against SARS-CoV-2 Following COVID-19 Vaccination in Older Adults: A Systematic Review.
Vaccines (Basel)
August 2025
CHANGE Research Working Group, Universidad Científica del Sur, Lima 15067, Peru.
Background: Evidence on the humoral and cellular immune responses to SARS-CoV-2 following COVID-19 vaccination in older adults is warranted.
Aims: To synthesize and analyze the current evidence on humoral and cellular immune responses to both standard and booster COVID-19 vaccination in individuals aged 60 years and older.
Methods: Clinical trials and observational studies were included.